Concomitant with a synergistic effect on cell viability, combining the PI3K/mTOR inhibitor NVP-BGT226 with the RNA synthesis inhibitor Mithramycin A increased the cytotoxicity and induced apoptosis in TFE3-fusion RCC cell lines (Fig. 5B; Supplementary Figure S9C). Here, MTOR is linked to renal cell carcinoma.